The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia
Abstract
The oral administration of finasteride, a 4-aza-steroid inhibitor of 5 alpha-reductase, decreases serum dihydrotestosterone levels, but has little effect on serum testosterone. The current study was designed to assess the effect of finasteride on dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. In a double blind, placebo-controlled study, 69 men with symptomatic prostatic hyperplasia were treated with placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate. In the placebo group the mean concentration of prostatic dihydrotestosterone was 10.3 +/- 0.6 nmol/kg (+/- SE), and the mean concentration of testosterone was 0.7 +/- 0.1 nmol/kg. After 7 days of treatment with all doses of finasteride, prostatic dihydrotestosterone declined to 15% or less of control levels, and the testosterone concentration increased in a reciprocal fashion. Compared to the placebo group, there was no significant difference in the mean prostatic dihydrotestosterone level achieved in any of the finasteride-treated groups. However, prostatic dihydrotestosterone levels were lower in the groups receiving higher doses of the drug. In two additional patients, finasteride treatment for 2 days also caused a decrease in prostatic dihydrotestosterone levels. No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
Dihydrotestosterone in prostatic hypertrophy
Siiteri, P. K., & Wilson, J. D. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106391 · Cited by 406
The pathogenesis of benign prostatic hyperplasia
Wilson, J. D. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90267-3 · Cited by 355
The Clinical Effects of a 5α-Reductase Inhibitor, Finasteride, on Benign Prostatic Hyperplasia
Stoner, E., & The Finasteride Study Group Participating clinics and investigators:S002253471737547X-bccd8dc81dd3b0b3e56165b279cc80b2 R.B. Bracken, S.-5. E. S. A. S.-E. K. F. U. O. C. M. C. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37547-x · Cited by 166
GORMLEY, G. J., STONER, E., RITTMASTER, R. S., GREGG, H., THOMPSON, D. L., LASSETER, K. C., VLASSES, P. H., & STEIN, E. A. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-4-1136 · Cited by 162
Geller, J. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-6-1552 · Cited by 126
Hormonal effects of an orally active 4‐azasteroid inhibitor of 5α‐reductase in humans
Vermeulen, A., Giagulli, V. A., Schepper, P. D., Buntinx, A., & Stoner, E. (1989) · The Prostate · doi:10.1002/pros.2990140106 · Cited by 106
4-Azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor.
Liang, T., Heiss, C. E., Cheung, A. H., Reynolds, G. F., & Rasmusson, G. H. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43519-8 · Cited by 103
Moore, R. J., Gazak, J. M., Quebbeman, J. F., & Wilson, J. D. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109536 · Cited by 99
Forti, G., SALERNO, R., Moneti, G., ZOPPI, S., Fiorelli, G., MARINONI, T., Natali, A., COSTANTINI, A., Serio, M., Martini, L., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-461 · Cited by 83
Cited by
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Self-citationFinasteride in the treatment of men with androgenetic alopecia
Kaufman, K. D., Olsen, E. A., Whiting, D., Savin, R., DeVillez, R., Bergfeld, W., Price, V. H., Van Neste, D., Roberts, J. L., Hordinsky, M., et al. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70007-6 · Cited by 772
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030330 · Cited by 467
Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2351 · Cited by 400
Metadata
- Authors
- McConnell, J. D.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1992-03-01
- Volume
- 74
- Issue
- 3
- Pages
- 505-508
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2023481449
- Cited by
- 325
- References
- 12
- FWCI
- 23.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. https://app.cochat.ai/papers/10.1210/jc.74.3.505
- The paper
- McConnell, J. D. (1992). Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.74.3.505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.